Scientists at the University of Göttingen generated polyklonal and monoclonal antibodies against the new diagnostic tumor marker PIWIL2. The tumor marker PIWIL2 is not present in normal cells (other than testicular), not present in inflammtory tissues but present in almost all cancer cell types. Because of its important role in tumor genesis and therefor early detection of tumors it could be used for first line screening. Monoclonal antibodies against PIWIL2 could be used for tissue analysis in surgery in clinics, detection of PIWIL2 in blood samples (ELISA) and monitoring of reponse to cancer treatment. Furthermore the antibodies could be used for targeting PIWIL2 within a cancer therapy.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
